China’s EV industry gets the attention, but biopharma is following the same trajectory. Know-how, speed, and cost advantages are making Chinese firms the innovation pipeline for Western pharma, increasingly displacing US startups as companies scramble to license and set up JVs.

Good post on how China's biotech industry went from laggard to leading in just 10 years. "A key mechanism in the Chinese system is the 60-day clock for clinical trial reviews."